The 12 analysts offering 12-month price forecasts for Denali Therapeutics Inc have a median target of 72.00, with a high estimate of 105.00 and a low estimate of 39.00. The median estimate represents a +130.47% increase from the last price of 31.24.
The current consensus among 14 polled investment analysts is to Buy stock in Denali Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.56
Reporting Date Aug 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.